Assessing the impact of diabetes on quality of life: what have the past 25 years taught us?

Diabetic Medicine - Tập 37 Số 3 - Trang 483-492 - 2020
Jane Speight1,2, Elizabeth Holmes‐Truscott1,2, Christel Hendrieckx1,2, Søren Skovlund3, Debbie Cooke4
1Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Melbourne, Victoria, Australia
2School of Psychology, Deakin University, Geelong, Victoria, Australia
3Steno Diabetes Centre Northern Denmark, Aalborg University Hospital, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
4School of Health Sciences, University of Surrey, Guildford, UK

Tóm tắt

AbstractOver the past 25 years, there has been significant acknowledgement of the importance of assessing the impact of diabetes on quality of life. Yet, despite the development of several diabetes‐specific quality of life measures, the challenges we faced in 1995 remain. There is little consensus on the definition of quality of life because of the complexity and subjectivity of the concept. General quality of life comprises several domains of life, and these are highly individualized. Assessing the impact of diabetes on these life domains adds to the complexity. While comprehensive diabetes‐specific quality‐of‐life measures typically increase respondent burden, brief questionnaires may not capture all relevant/important domains. Today, the lack of resolution of these challenges may explain why the impact of diabetes on quality of life is not systematically assessed in research or clinical care. Few researchers report detailed rationales for assessment, there is often a mismatch between the concept of interest and the measure selected, and data are misinterpreted as assessing the impact of diabetes on quality of life when, in reality, related but distinct constructs have been assessed, such as diabetes distress, treatment satisfaction or health status. While significant efforts are being made to increase routine monitoring of psychological well‐being and understand the lived experience, no guidelines currently recommend routine clinical assessment of diabetes‐specific quality of life, and there is no consensus on which questionnaire(s) to use. The gaps identified in this review need urgent attention, starting with recognition that assessment of diabetes‐specific quality of life is as important as biomedical markers, if we are to improve the lives of people with diabetes.

Từ khóa


Tài liệu tham khảo

10.1136/bmj.323.7319.994

10.2337/diacare.11.9.725

10.1126/science.847460

Kowitt SD, 2018, Principles and Concepts of Behavioral Medicine: A Global Handbook

Spilker B, 1996, Quality of Life and Pharmacoeconomics Trials

10.1017/S0033291700022388

10.1177/140349488201000204

10.1136/jme.10.3.124

Jacobson AM, 1994, Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice

10.2337/diacare.19.3.195

10.1016/S0140-6736(00)03562-5

10.2337/diacare.22.7.1125

10.1002/(SICI)1520-7560(199905/06)15:3<205::AID-DMRR29>3.0.CO;2-O

Australian Centre on Quality of Life.Directory of Instruments.http://wwwacqolcomau/instruments#measures2019.

10.1111/j.1464-5491.2009.02682.x

Polonsky WH, 2000, Understanding and assessing diabetes‐specific quality of life, Diabetes Spectrum, 13, 36

10.2337/diacare.21.5.757

10.1023/A:1026485130100

10.2337/dc12-0076

10.1007/s10865-015-9649-y

Peyrot M, 1994, Living with diabetes: the patient‐centred perspective, Diabetes Spectrum, 7, 204

Schlundt DG, 1996, Practical Psychology for Diabetes Clinicians: How to deal with the key behavioural issues faced by patients and health care teams

10.1023/A:1013159414364

10.1111/j.1464-5491.2005.01644.x

10.1111/dme.13178

10.1016/j.diabres.2019.03.020

10.1111/dme.12245

US Department of Health and Human Services FDA Center for Drug Evaluation and Research US Department of Health and Human Services FDA Center for Biologics Evaluation and Research US Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for Industry: Patient‐Reported Outcome Measures: Use in medical product development to support labeling claims. Available athttps://www.fda.gov/media/77832/downloadLast accessed 23 Jan 2020.

10.1007/BF00284453

Speight J, 2002, DAFNE: improved quality of life with intensified treatment is counter‐intuitive to many clinicians, BMJ

10.1002/dmrr.279

10.1136/bmj.325.7367.746

10.2337/db19-809-P

Schipp J, 2019, A qualitative investigation of the acceptability to adults with type 1 diabetes of five diabetes‐specific quality of life measures. Findings of the YourSAY: Quality of Life study (193), Australasian Diabetes Congress

10.1136/adc.84.3.205

10.1186/1477-7525-2-61

10.1002/pdi.348

10.2174/157339912803529850

10.2337/dci17-0005

Sinclair A, 2013, Quality of life in older people with diabetes, Nursing Practice

10.1111/j.1464-5491.2012.03748.x

10.1111/dme.12620

International Consortium for Health Outcomes Measurement.Measuring Results that Matter: Type 1 and Type 2 Diabetes in Adults Data Collection Reference Guide. Version 1.0.0. Available at:https://ichom.org/files/medical-conditions/diabetes-in-adults/dia-reference-guide.pdfLast accessed 23 Jan 2020.

WHO and IDF in Europe, 1997, The St Vincent Declaration on the Treatment of Diabetes, Acta Ophthalmol Scand, 75, 63, 10.1111/j.1600-0420.1997.tb00440.x

10.1111/j.1464-5491.1994.tb00316.x

Speight J, Back to the future: 25 years of ‘Guidelines for Encouraging Psychological Well‐being’ among people affected by diabetes, Diabet Med

10.2337/dc11-1326

10.1111/pedi.12237

10.1111/dme.12768

10.1111/dme.14048

Thông tin
Thông tin xuất bản

Diabetic Medicine

Tập 37 Số 3

483-492

Thông tin tác giả